Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (29,864)	$ (32,102)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,248	1,543
Non-cash research and development arrangements	390	1,205
Amortization of customer warrant	0	219
Stock-based compensation	22,561	5,929
Change in fair value of warrant liabilities	(28,358)	0
Offering costs associated with warrants	0	4,259
Other, net	(38)	184
Changes in operating assets and liabilities:
Accounts receivable	(1,135)	(3,691)
Prepaid expenses and other current assets	(1,842)	(3,950)
Accounts payable	2,992	(1,191)
Accrued expenses	1,996	1,714
Unearned revenue	(555)	4,084
Other assets and liabilities	(180)	(54)
Net cash used in operating activities	(29,785)	(21,851)
Cash flows from investing activities:
Purchases of property and equipment	(8,381)	(5,295)
Capitalized software development costs	(1,491)	(1,205)
Intangible asset acquisition costs	(598)	(414)
Purchases of available-for-sale securities	(488,887)	0
Maturities of available-for-sale securities	185,150	0
Net cash used in investing activities	(314,207)	(6,914)
Cash flows from financing activities:
Proceeds from stock options exercised	953	5,424
Tax withholding receipts related to vested and released RSUs	1,212	0
Tax withholding payments related to vested and released RSUs	(17)	0
Proceeds from public warrants exercised	17	0
Repurchase of early exercised stock options	0	(968)
Proceeds from merger and PIPE transactions, net of transaction costs	0	575,483
Net cash provided by financing activities	2,165	579,939
Net change in cash and cash equivalents	(341,827)	551,174
Cash and cash equivalents at the beginning of the period	399,025	36,120
Cash and cash equivalents at the end of the period	57,198	587,294
Supplemental disclosure of non-cash investing and financing transactions:
Issuance of common stock for intellectual property	0	1,567
Issuance of common stock for research and development arrangement	0	814
Property and equipment purchases in accounts payable and accrued expenses	186	309
Intangible asset purchases in accounts payable and accrued expenses	256	129
Noncash reclassification of warrant liabilities to equity upon exercise	8	0
Bonus settled in restricted stock units	473	0
Transaction costs in accounts payable and accrued expenses	$ 0	$ 2,620